Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial
Kenneth H. Mayer, Kelly E. Seaton, Yunda Huang et al. · PLOS Medicine · 2017 · Randomised trial
Full textCC0